ENSC ▲ +2.1% - Ensysce Biosciences, Inc. $ENSC - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation Ensysce Biosciences rose 2.1% today following announcements that the company is advancing its Complex Regional Pain Syndrome (CRPS) program at Painweek 2026 and contributing to an FDA hearing on psychedelic drug regulation. The dual developments signal progress in the company's pain management pipeline and regulatory engagement in an emerging therapeutic area, which appears to have resonated positively with investors. 15-SEP-2026 09:15 AM ET